Clinical Trials

Breast Neoplasms

NCT06340165 2024-04-01

A Real-world Efficacy and Safety Study of Amlotinib for HER2-negative Advanced Breast Cancer

Unknown

153 enrolled

Breast Neoplasms

NCT06277674 2024-03-08

Efficacy of Cadonilimab in Non-squamous Non-small Cell Lung Cancer Patients Resistant to EGFR-TKI

Carcinoma, Non-Small-Cell Lung

NCT05029102 2024-02-12

TAS-102 and Anlotinib in ≥3 Lines mGC

45 enrolled

Stomach Neoplasms

NCT04914390 2024-01-22

NeoATCT

32 enrolled

Triple Negative Breast Neoplasms

NCT04197492 2024-01-05

Hypofractionated Stereotactic Radiotherapy With Anlotinib in Patients With Recurrent High-Grade Gliomas

22 enrolled

CNS

Glioma

NCT03646968 2023-12-27

SAVE

43 enrolled

Non-Squamous Non Small Cell Lung Cancer

NCT05028504 2023-12-27

ALTER-GO-020

86 enrolled

Gynecological Cancer

NCT04985851 2023-12-01

To Evaluate the Efficacy of Durvalumab + Anlotinib in Terms of OS and PFS.

90 enrolled

Small Cell Lung Carcinoma

NCT05262335 2023-11-28

ALTER-G-001

116 enrolled

Digestive System Neoplasms

NCT02584478 2023-11-08

AL3818

Phase 3 Unknown

294 enrolled

Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT05490667 2023-10-30

Clinical Study of Anlotinib Combined With Chemotherapy in the Treatment of Unresectable Advanced Desmoid Tumor

Desmoid Tumors

NCT05296577 2023-09-25

Anlotinib Combination With Vinorelbine in the HER2- Advanced Breast Cancer

134 enrolled

Breast Neoplasms

NCT06031480 2023-09-11

FAITH

55 enrolled

Carcinoma, Hepatocellular

NCT06015126 2023-08-29

Efficacy and Safety of Metronomic Oral Vinorelbine Plus Anlotinib in HER2-negative Metastatic Breast Cancer Patients

60 enrolled

Breast Neoplasms

NCT03890068 2023-08-01

Anlotinib Maintenance Treatment for Advanced Soft Tissue Sarcoma

48 enrolled

NCT04803851 2023-06-22

Anlotinib Plus Anti-PD-1 Antibody AK105 for Advanced Pancreatic Cancer

Phase 1/2 Unknown

29 enrolled

Anlotinib

NCT05896059 2023-06-09

A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Anlotinib as Maintenance Therapy for ES-SCLC

21 enrolled

Extensive Stage Small Cell Lung Cancer

NCT05883085 2023-05-31

A Study on the Safety and Effectiveness of Anlotinib for Neoadjuvant Treatment of PPGL

10 enrolled

CNSEndocrine

Paraganglioma, Pheochromocytoma

NCT05866510 2023-05-19

Utidelone and Anlotinib in Advanced Recurrent Metastatic Esophageal Cancer

47 enrolled

Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT05842018 2023-05-03

Toripalimab in Combination With Chemotherapy and Antiangiogenic Agents in Patients With Non-Small Cell Lung Cancer After Failure of Immunotherapy (PD-1/L1 Inhibitors)

Non Small Cell Lung Cancer Recurrent

NCT04172805 2023-04-12

Anlotinib Combined With Toripalimab in Refractory and Advanced Soft-tissue Sarcoma

70 enrolled

NCT05218629 2023-03-29

Anlotinib Plus PD-1 Inhibitor as 2nd-line Threapy in Patients With Metastatic Pancreatic Cancer

Overall Survival

NCT04895930 2023-01-06

FOCUS-A

Carcinoma, Non-Small-Cell Lung

NCT05659186 2022-12-21

PD-1 Inhibitor and Anlotinib Combined With Multimodal Radiotherapy in Recurrent or Metastatic Anaplastic Thyroid Cancer

Head & Neck

Thyroid Neoplasms

NCT05602415 2022-11-02

Anlotinib and Radiotherapy in Resectable Soft Tissue Sarcoma

41 enrolled

NCT05558722 2022-09-28

ACNTBC

Breast Neoplasms

NCT05485350 2022-08-03

Anlotinib , Penpulimab Combined With SBRT for Metastatic Non-Small Cell Lung Cancer (NSCLC)

32 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05460481 2022-07-20

Anlotinib Plus Penpulimab in Advanced Non-Small-Cell Lung Cancer Previously Treated With PD-1/PD-L1 Inhibitors

29 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05460195 2022-07-15

Sintilimab Combined With Anlotinib for Perioperative Non-small Cell Lung Cancer Based on MRD Evaluation

42 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasm, Residual

NCT05387109 2022-05-24

pcwaintrl

Phase 4 Unknown

41 enrolled

NSCLC

NCT05385068 2022-05-23

t

35 enrolled

Carcinoma, Ovarian Epithelial

NCT05385900 2022-05-23

ICTCPTLAGC

57 enrolled

Stomach Neoplasms

NCT05319886 2022-05-20

AP

Unknown

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05311579 2022-04-13

Niraparib Plus Anlotinib for Recurrent Ovarian Cancer

36 enrolled

Ovarian Neoplasms

NCT05322499 2022-04-11

Phase II Clinical Study of Camrelizumab Combined With Chemotherapy or Anlotinib in Advanced Esophageal Squamous Cell Cancer

80 enrolled

Esophageal Squamous Cell Carcinoma

NCT05306847 2022-04-01

Sintilimab Combined With Anlotinib Therapy for Initially Unresectable Non-small Cell Lung Cancer

93 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04325763 2022-03-31

A Study of TQB2450 in Subjects With Stage III Non-Small Cell Lung Cancer(NSCLC)

Phase 3 Unknown

315 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04970914 2022-03-08

ALTER-C003

32 enrolled

Colorectal Neoplasms

NCT05218759 2022-02-01

Exosomes Detection for the Prediction of the Efficacy and Adverse Reactions of Anlotinib in Patients With Advanced NSCLC

Carcinoma, Non-Small-Cell Lung

NCT05089643 2022-01-10

Anrotinib in Combination With Capecitabine in Advanced Triple Negative Breast Cancer

35 enrolled

Triple Negative Breast Neoplasms

NCT05137171 2021-11-30

AK105 Combined With Anlotinib in Patients With Cervical Cancer

36 enrolled

Uterine Cervical Neoplasms

NCT05133349 2021-11-24

EASOAIPPGL

CNSEndocrine

Paraganglioma, Pheochromocytoma

NCT04731038 2021-09-17

Combination Therapy for First Line Treatment of Advanced Cervical Cancer

Phase 1 Unknown

Advanced Cervical Cancer

NCT03387904 2021-09-02

Study of Anlotinib Plus Irinotecan in Patients With Esophageal Squamous Cell Carcinoma

120 enrolled

Esophageal Squamous Cell Carcinoma

NCT05030077 2021-09-01

Anlotinib Combined With Platinum/Gemcitabine for First Line Treatment of Advanced Urothelial Carcinoma

53 enrolled

Genitourinary

Carcinoma, Transitional Cell, Urogenital Neoplasms

NCT04846452 2021-08-12

Sintilimab, Anlotinib Hydrochloride and Platinum-Containing Dual-Agent Chemotherapy in NSCLC

Carcinoma, Non-Small-Cell Lung

NCT04999800 2021-08-11

Study of Pembrolizumab Combined With Anlotinib in the First Line Therapy for R/M HNSCC With CPS≥1

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT04979585 2021-08-03

Camrelizumab Plus Amlotinib and Chemotherapy in the First-line Treatment of Melanoma

66 enrolled

Dermatologic

Melanoma

NCT04975451 2021-07-27

ADCb (Anlotinib/Docetaxel/Carboplatin) as Neoadjuvant Therapy for Triple-Negative Breast Cancer